Dannalab

Executive Summary

Dannalab is a Netherlands-based contract research organization specializing in cGMP-compliant X-ray powder diffraction (XRPD) and small-angle X-ray scattering (SAXS) testing for pharmaceutical and biopharmaceutical CMC (Chemistry, Manufacturing, and Controls). Founded in 2018, the company provides method development, validation, batch release, stability studies, and patent analysis services, delivering regulatory-ready documentation. As a niche player in solid-state characterization, Dannalab supports drug development by ensuring compliance with stringent regulatory standards, which is critical for quality control and formulation optimization. The company operates in the growing microbiome and diagnostics sectors, leveraging advanced analytical techniques to address unmet needs in drug substance and product characterization. While financial details remain undisclosed, Dannalab's focus on cGMP compliance and its strategic location in Amsterdam position it to capture demand from European pharma and biotech firms seeking specialized analytical support for regulatory submissions.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with Major Pharmaceutical Company50% success
• Q4 2026Expansion of Service Portfolio to Include Complementary Techniques40% success
• Q2 2027Regulatory Approval or Endorsement of Analytical Methods30% success